作者
Scott R. Plotkin,Ludwine Messiaen,Eric Legius,Patrice Pancza,Robert A. Avery,Jaishri O. Blakeley,Dusica Babovic‐Vuksanovic,Rosalie E. Ferner,Michael J. Fisher,Jan M. Friedman,Marco Giovannini,David H. Gutmann,C. Oliver Hanemann,Michel Kalamarides,Hildegard Kehrer‐Sawatzki,Bruce R. Korf,Victor‐Felix Mautner,Mia MacCollin,Laura Papi,Katherine A. Rauen,Vincent M. Riccardi,Elizabeth K. Schorry,Miriam J. Smith,Anat Stemmer‐Rachamimov,David A. Stevenson,Nicole J. Ullrich,David Viskochil,Katharina Wimmer,Kaleb Yohay,Susan Huson,P. Wolkenstein,D. Gareth Evans,Monique Anten,Arthur S. Aylsworth,Diana Baralle,S. Barbarot,Fred G. Barker,Shay Ben‐Shachar,Amanda Bergner,D. Bessis,Ignacio Blanco,Cathérine Cassiman,Patricia Ciavarelli,Maurizio Clementi,Thierry Frébourg,Alicia Gomes,Dorothy Halliday,Chris Hammond Helen Hanson Arvid Heiberg,K.H. Ly,Justin T. Jordan,Matthias A. Karajannis,Daniela Kroshinsky,Margarita Larralde,Conxi Lázaro,Lu Q. Le,Michael P. Link,Robert Listernick,Conor Mallucci,Vanessa L. Merker,Christopher L. Moertel,Amy Mueller,Joanne Ngeow,Rianne Oostenbrink,Roger J. Packer,Allyson Parry,Juha Peltonen,Dominique C. Pichard,Bruce Poppe,Nilton Alves de Rezende,Luiz Oswaldo Carneiro Rodrigues,Tena Rosser,Martino Ruggieri,Eduard Serra,Verena Steinke‐Lange,Stavros Stivaros,Amy Taylor,Jaan Toelen,James H. Tonsgard,Eva Trevisson,Meena Upadhyaya,Ali Varan,Meredith Wilson,Hao Wu,Gelareh Zadeh
摘要
Neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) are genetically distinct tumor predisposition syndromes with overlapping phenotypes. We sought to update the diagnostic criteria for NF2 and SWN by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging.We used a multistep process, beginning with a Delphi method involving global disease experts and subsequently involving non-neurofibromatosis clinical experts, patients, and foundations/patient advocacy groups.We reached consensus on the minimal clinical and genetic criteria for diagnosing NF2 and SWN. These criteria incorporate mosaic forms of these conditions. In addition, we recommend updated nomenclature for these disorders to emphasize their phenotypic overlap and to minimize misdiagnosis with neurofibromatosis type 1.The updated criteria for NF2 and SWN incorporate clinical features and genetic testing, with a focus on using molecular data to differentiate the 2 conditions. It is likely that continued refinement of these new criteria will be necessary as investigators study the diagnostic properties of the revised criteria and identify new genes associated with SWN. In the revised nomenclature, the term "neurofibromatosis 2" has been retired to improve diagnostic specificity.